Definitive Treatment for Extrahepatic Portal Venous Obstruction (EHPVO)
In children with patent superior mesenteric and left portal veins, the meso-Rex bypass is the definitive treatment of choice, offering physiological restoration of portal flow with high long-term patency and effective prevention of all portal hypertension complications. 1, 2, 3
Treatment Strategy Based on Age and Anatomy
Children with EHPVO
The meso-Rex shunt (mesenterico-Rex bypass) should be performed when the superior mesenteric vein and left portal vein are patent. 1, 2, 3 This procedure:
- Achieves high feasibility and long-term patency 1
- Effectively prevents gastrointestinal bleeding 1
- Improves mental status and coagulation factor levels 1
- Addresses both bleeding and non-bleeding sequelae including growth retardation, portal biliopathy, and quality of life impairment 4, 3
- Represents the standard-of-care surgery in pediatric EHPVO 2
The surgical technique involves constructing a bypass between the superior mesenteric vein and the Rex recess of the left portal vein, restoring physiological hepatic portal flow 1, 5, 3. Various conduits can be used, including autologous internal jugular vein, recanalized umbilical vein, or prosthetic grafts, though pure venous grafts demonstrate superior patency (85.7%) compared to prosthetic grafts (42.9%) 6, 5.
Adults with EHPVO
For adults, treatment selection depends on vascular anatomy and clinical presentation:
When Surgical Shunting is Feasible:
- Surgical portosystemic shunting using superior mesenteric or splenic veins achieves low mortality and rebleeding rates in selected patients 1
- Meso-Rex bypass can be performed in adults when anatomy permits, achieving symptom relief in 85.7% of patients, though it carries major morbidity (35.7%) and mortality risk and should only be performed at tertiary centers experienced in vascular liver surgery 6
When Intrahepatic Portal Veins are Visible:
Portal vein recanalization (PVR) without TIPS insertion demonstrates 73% primary patency at 5 years and controls portal hypertension complications in 78% of patients 7
This approach is associated with improved muscle mass and decreased spleen volume 7
PVR failure is associated with extension into intrahepatic portal veins and recanalizations performed for abdominal pain 7
Covered TIPS insertion is feasible but data are limited to short-term follow-up (average 18 months) 1
Encephalopathy occurs at similar rates as in cirrhotic patients 1
Management of Portal Hypertension Complications
Variceal Bleeding Prevention:
Beta-adrenergic blockade decreases bleeding risk in patients with large varices and improves survival 1
Endoscopic variceal band ligation is superior to sclerotherapy 1
- In children, band ligation alone or combined with sclerotherapy provides effective prophylaxis 1
- In adults, propranolol and band ligation show equivalent rebleeding rates (approximately 20% at two years) for non-cirrhotic portal hypertension 1
Portal Cholangiopathy:
Only patients with clinical manifestations require specific treatment 1
- Bile stones should be treated endoscopically, though risk of haemobilia from ruptured intrabiliary varices exists 1
- Biliary strictures with jaundice can be managed with repeated endoscopic stenting 1
- Surgical shunts should be considered when superior mesenteric or splenic veins are patent 1
Anticoagulation Strategy
Once prophylaxis for gastrointestinal bleeding has been implemented, long-term anticoagulation should be considered 1:
- Anticoagulation reduces recurrent thrombosis risk (risk ratio 0.39) 1
- It improves survival with statistically significant mortality reduction 1
- Bleeding severity on anticoagulation is similar to patients without anticoagulation when bleeding prophylaxis is routinely performed 1
- Permanent anticoagulation is indicated for underlying myeloproliferative neoplasms 1
- Consider permanent anticoagulation for strong prothrombotic conditions or history of intestinal ischemia 1
Critical Pitfalls to Avoid
Do not perform meso-Rex bypass in adults outside tertiary centers with vascular liver surgery expertise, as mortality and major morbidity rates are significant 6. The procedure requires median operative times of 500 minutes and carries a 35.7% major morbidity rate 6.
Avoid prosthetic grafts when possible for meso-Rex bypass, as patency rates (42.9%) are substantially lower than pure venous grafts (85.7%) 6.
Do not delay surgical evaluation in children, as endotherapy alone fails to address non-bleeding sequelae including growth retardation, portal biliopathy, and impaired quality of life that persist despite variceal eradication 4, 3.